Mode
Text Size
Log in / Sign up
N/A N=55

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1

Neurofibromatosis 1

Enrolled (actual)
55
Serious AEs
Results posted
May 2025
Primary outcome: Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Blood draw (Diagnostic_test); FACIT-F and Pain Scales (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Arkansas
Primary completion
Aug 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Mitochondrial Respiration Efficiency (as Measured by OCR).
67.7167; 53.7000; 73.3358; 68.5789 <0.01 sig
PRIMARY
Mitochondrial Respiration Efficiency (as Measured by ECAR).
29.6667; 19.8500; 32.4583; 33.0467 0.54
PRIMARY
Vitamin D Levels
33.665909090909 0.36
PRIMARY
Pain (as Measured With NRS-11 for Current Pain Over the Past 24 Hours) of NF1 Patients
2.70; 2.05; 1.78 <0.01 sig
PRIMARY
Pain (as Measured With NRS-11 for Best Pain Over the Past 24 Hours) of NF1 Patients
1.95; 1.41; 1.53 0.02 sig
PRIMARY
Pain (as Measured With NRS-11 for Worst Pain Over the Past 24 Hours) of NF1 Patients
4.77; 3.38; 2.61 0.03 sig
PRIMARY
Fatigue (as Measured FACIT-F TOI) of NF1 Patients.
71.9943; 73.1752; 75.3935 0.88

Summary

Neurofibromatosis type 1 is a common genetic disease with a broad spectrum of clinical manifestations in multiple organs of the body. This project will study the (dys)function of mitochondria in patients with neurofibromatosis through multiple collections of blood samples from patients and people not afflicted by neurofibromatosis (control group). This study will evaluate how the function of mitochondria changes with time and if medications and supplements can influence the function of the mitochondria. Patients will also answer questions regarding symptoms like fatigue and pain.

Eligibility Criteria

NF1 Group:

Inclusion Criteria

  • Diagnosed with NF1

Inclusion Criteria

  • Not the first degree relative (biological parent, sibling, or child) of the NF1 patient who is in the NF1 group
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05912400). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search